Interphase FISH Does Not Improve the Detection of DEL(5q) and DEL(20q) in Myelodysplastic Syndromes

被引：0
|
作者：
Douet-Guilbert, Nathalie [1 ,2 ,3 ]
Herry, Angele [1 ]
Le Bris, Marie-Josee [2 ]
Gueganic, Nadia [1 ]
Bovo, Clement [1 ]
Morel, Frederic [1 ,2 ,3 ]
De Braekeleer, Marc [1 ,2 ,3 ]
机构：
[1] Univ Bretagne Occidentale, Lab Histol Embryol & Cytogenet, Fac Med & Sci Sante, F-29238 Brest 3, France
[2] CHU Brest, Hop Morvan, Serv Cytogenet Cytol & Biol Reprod, F-29285 Brest, France
[3] INSERM, U613, Brest, France
来源：
ANTICANCER RESEARCH | 2011年 / 31卷 / 03期
关键词：
Interphase FISH; MDS; normal karyotype; del(5q); del(20q); IN-SITU HYBRIDIZATION; SCORING SYSTEM; MYELOPROLIFERATIVE DISORDERS; CONVENTIONAL CYTOGENETICS; MOLECULAR CYTOGENETICS; CLASSIFICATION; DIAGNOSIS; DELETION; ABERRATIONS; TRISOMY-8;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cytogenetic abnormalities identified by conventional cytogenetics (CC) have important prognostic and therapeutic roles in myelodysplastic syndromes (MDS). Fluorescence in situ hybridization (FISH) complements CC since it is able to evaluate large numbers of interphase and metaphase nuclei. The question has been raised as to whether interphase FISH in addition to CC is able to imprive the level of detection of del(5q) and del(20q) in MDS. This study performed interphase FISH with 5q and 20q probes in a series of 158 MDS patients with a normal karyotype. No hidden del(5q) or del(20q) was detected. A review of the literature identified 20 patients (1.96%) of 1018 patients (including the current series) and 3 (0.91%) of 331 patients to have a del(5q) or del(20q). Therefore, interphase FISH adds little, if any, improvement to the probability of detecting these deletions. However, interphase FISH is recommended in patients with no cell growth or when fewer than 20 metaphases are available for CC analysis.
引用
收藏
页码：1007 / 1010
页数：4
相关论文
共 50 条
  • [21] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [22] Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
    Heise, Carla
    Carter, Troy
    Schafer, Peter
    Chopra, Rajesh
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1663 - 1672
  • [23] Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
    Mallo, Mar
    del Rey, Monica
    Ibanez, Mariam
    Jose Calasanz, Ma
    Arenillas, Leonor
    Jose Larrayoz, Ma
    Pedro, Carmen
    Jerez, Andres
    Maciejewski, Jaroslaw
    Costa, Dolors
    Nomdedeu, Meritxell
    Diez-Campelo, Maria
    Lumbreras, Eva
    Gonzalez-Martinez, Teresa
    Marugan, Isabel
    Such, Esperanza
    Cervera, Jose
    Cigudosa, Juan C.
    Alvarez, Sara
    Florensa, Lourdes
    Hernandez, Jesus Ma
    Sole, Francesc
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (01) : 74 - 86
  • [24] Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella, Federico
    Latagliata, Roberto
    Carmosino, Ida
    Volpicelli, Paola
    Montagna, Chiara
    Romano, Angela
    Roberto, Amanda
    Finsinger, Paola
    Mancini, Marco
    Breccia, Massimo
    Oliva, Esther
    Alimena, Giuliana
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (01) : 48 - 51
  • [25] Survival of patients with de novo myelodysplastic syndromes (MDS) and del(5q)
    Gritsaev, S.
    Martinkevitch, I.
    Petrova, E.
    Kostroma, I.
    Ivanova, M.
    Sergeev, A.
    Tiranova, S.
    Potichonova, N.
    LEUKEMIA RESEARCH, 2013, 37 : S88 - S88
  • [26] CYTOGENETIC CLONAL EVOLUTION IN MYELODYSPLASTIC SYNDROMES (MDS) WITH ISOLATED DEL(5Q)
    Zemanova, Z.
    Michalova, K.
    Brezinova, J.
    Svobodova, K.
    Lhotska, H.
    Sarova, I.
    Lizcova, L.
    Izakova, S.
    Ransdorfova, S.
    Pavlistova, L.
    Berkova, A.
    Skipalova, K.
    Belickova, M.
    Siskova, M.
    Neuwirtova, R.
    Cermak, J.
    Stopka, T.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2017, 55 : S56 - S57
  • [27] Myelodysplastic Syndrome of del 20q with Plasma Cell Dysplasia
    Saito, Nagahito
    Higashiura, Katsuhiro
    Ehata, Kazunori
    Kurosawa, Shinji
    Honma, Kenta
    Abe, Masayuki
    Kimura, Akihiko
    Suzuki, Mio
    Nakamura, Shigeo
    Shiku, Hiroshi
    Ooi, Hong Kean
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2011, 51 (02) : 141 - 145
  • [28] Familial occurrence of myelodysplastic syndrome with del(5q)
    Volpicelli, Paola
    Latagliata, Roberto
    Carmosino, Ida
    Breccia, Massimo
    Vozella, Federico
    Mancini, Marco
    Cannella, Laura
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2011, 52 (06) : 1143 - 1145
  • [29] Familiar occurrence of myelodysplastic sydrome with del(5q)
    Napoleone, L.
    Latagliata, R.
    Breccia, M.
    Vozella, F.
    Carmosino, I.
    De Cuia, R.
    Mancini, M.
    Volpicelli, P.
    Stefanizzi, C.
    Cannella, L.
    Mercanti, C.
    Alimena, G.
    LEUKEMIA RESEARCH, 2009, 33 : S97 - S98
  • [30] Clinical significance of del(20q) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Tedeschi, A
    Montillo, M
    Hayes, KJ
    Di Raimondo, F
    Lerner, S
    Morra, E
    Estey, E
    Keating, MJ
    BLOOD, 2000, 96 (11) : 709A - 709A
12345